Copenhagen University Hospital
- Address
- lock Available on a paid plan
Neurocritical Care and Seizure Disorders
At Copenhagen University Hospital, the Department of Neuroanaesthesiology is involved in research on nervous system diseases, with a focus on severe seizure emergencies such as refractory status epilepticus. These studies are designed to assess whether new treatments can improve seizure control, safety, and tolerability when standard care is not enough.
- Evaluating a new therapy added to standard anti-seizure treatment for refractory status epilepticus
- Studying better ways to manage life-threatening seizure activity in emergency care
The research reflects a strong interest in improving outcomes for patients with urgent neurologic conditions.
Thoracic Oncology and Immunotherapy
This site also supports clinical research in neoplasms, especially malignant pleural mesothelioma. The trials are exploring whether immune-based treatments can help patients whose disease has progressed after earlier chemotherapy, with the goal of improving treatment effectiveness in a difficult-to-treat cancer.
- Testing immunotherapy combinations for malignant pleural mesothelioma
- Exploring whether adding a vaccine approach may strengthen cancer control
These studies contribute to the broader search for better options in advanced respiratory tract-related cancers.
Metabolic Health and Obesity Research
Clinical trials at Copenhagen University Hospital include work in nutritional and metabolic diseases, particularly obesity and related cardiovascular risk. The research aims to determine whether new treatments can support weight management while also improving long-term heart and vascular safety.
- Assessing a potential treatment for people with overweight or obesity
- Examining cardiovascular safety alongside metabolic benefit
These efforts highlight interest in therapies that address both body weight and broader metabolic health.
Rare Endocrine and Congenital Disorders
Research in congenital, hereditary, and neonatal diseases includes studies of congenital adrenal hyperplasia, a rare endocrine condition. The purpose of this work is to evaluate new treatment options that may better support disease control and improve quality of life for people living with this inherited disorder.
- Investigating a new therapy for congenital adrenal hyperplasia
- Advancing care for a rare inherited hormonal disorder
Across these trials, the site demonstrates a broad commitment to both rare disease research and clinically urgent conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Avidity Biosciences Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Avidity Biosciences Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Copenhagen University Hospital
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus | Marinus Pharmaceuticals Inc. | Phase III | Not Recruiting | Nov 2023 | Apr 2024 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker | 2 | Unknown | 2024-12-11 | 2026-01-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.